Hester Biosciences Limited (IN:HESTERBIO)
:HESTERBIO
Top Page
Hester Biosciences Limited
(HESTERBIO)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹1,506.00
▼(-6.21% Downside)
Action:ReiteratedDate:10/23/25
Hester Biosciences Limited's overall stock score is primarily supported by its strong financial performance, which indicates robust revenue and profit growth. However, the technical analysis suggests bearish momentum, and the valuation indicates the stock might be overvalued. These factors contribute to a moderate overall score.
Positive Factors
Revenue & Margin Growth
Hester's income statement shows durable revenue growth alongside rising gross, EBIT and EBITDA margins. Sustained margin expansion indicates improving operational efficiency and pricing power in its vaccine franchise, supporting long-term profitability resilience.
Negative Factors
Rising Debt Trend
The financial summary flags an increase in total debt that warrants monitoring. Rising leverage can raise interest costs, limit capital allocation flexibility, and heighten vulnerability to revenue volatility, potentially constraining strategic investments if not addressed.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Margin Growth
Hester's income statement shows durable revenue growth alongside rising gross, EBIT and EBITDA margins. Sustained margin expansion indicates improving operational efficiency and pricing power in its vaccine franchise, supporting long-term profitability resilience.
Read all positive factors
Hester Biosciences Limited (HESTERBIO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹12.15B
Dividend Yield0.44%
Average Volume (3M)308.00
Price to Earnings (P/E)38.8
Beta (1Y)0.71
Revenue Growth-3.84%
EPS Growth86.82%
CountryIN
Employees642
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)10.30
Shares Outstanding8,506,865
10 Day Avg. Volume428
30 Day Avg. Volume308
Financial Highlights & Ratios
PEG Ratio0.96
Price to Book (P/B)3.84
Price to Sales (P/S)3.88
P/FCF Ratio27.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hester Biosciences Limited Business Overview & Revenue Model
Company Description
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates in two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for dis...
How the Company Makes Money
Hester Biosciences makes money primarily by selling veterinary vaccines and other animal healthcare products. Its core revenue stream comes from commercialization of its vaccine portfolio for poultry and large animals through sales to distributors...
Hester Biosciences Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.00B | 3.11B | 3.05B | 2.66B | 2.35B | 2.14B |
| Gross Profit | 2.00B | 2.08B | 972.64M | 1.89B | 1.66B | 1.58B |
| EBITDA | 670.92M | 649.76M | 582.46M | 619.20M | 731.93M | 700.21M |
| Net Income | 438.44M | 274.88M | 188.89M | 266.27M | 393.20M | 344.30M |
Balance Sheet | ||||||
| Total Assets | 6.75B | 6.53B | 6.62B | 6.70B | 5.62B | 4.11B |
| Cash, Cash Equivalents and Short-Term Investments | 281.58M | 72.19M | 153.04M | 148.17M | 252.20M | 212.69M |
| Total Debt | 2.14B | 2.13B | 2.44B | 2.74B | 2.28B | 1.10B |
| Total Liabilities | 3.24B | 3.27B | 3.59B | 3.81B | 2.95B | 1.75B |
| Stockholders Equity | 3.38B | 3.14B | 2.92B | 2.80B | 2.60B | 2.28B |
Cash Flow | ||||||
| Free Cash Flow | 91.06M | 439.20M | 237.37M | -541.66M | -869.02M | 173.11M |
| Operating Cash Flow | 174.78M | 645.11M | 481.34M | 235.96M | 88.08M | 580.53M |
| Investing Cash Flow | -22.74M | -190.03M | -226.54M | -769.99M | -1.17B | -383.72M |
| Financing Cash Flow | -155.89M | -517.17M | -260.45M | 417.58M | 1.12B | -182.19M |
Hester Biosciences Limited Technical Analysis
Neutral
1605.75
Price Trends
1470.87
Negative
1540.84
Negative
1711.12
Negative
Market Momentum
-41.32
Positive
50.14
Neutral
53.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HESTERBIO, the sentiment is Neutral. The current price of 1605.75 is above the 20-day moving average (MA) of 1412.10, above the 50-day MA of 1470.87, and below the 200-day MA of 1711.12, indicating a neutral trend. The MACD of -41.32 indicates Positive momentum. The RSI at 50.14 is Neutral, neither overbought nor oversold. The STOCH value of 53.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:HESTERBIO.
Hester Biosciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | ₹12.15B | 38.81 | ― | 0.44% | -3.84% | 86.82% | |
61 Neutral | ₹21.01B | 2.94 | ― | ― | 25.42% | ― | |
57 Neutral | ₹29.06B | 67.80 | ― | 0.03% | 7.78% | -34.68% | |
57 Neutral | ₹20.81B | 20.54 | ― | 0.49% | -0.29% | -29.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ₹17.32B | -18.14 | ― | 0.08% | -2.81% | -444.69% |
* Healthcare Sector Average
IN:HESTERBIO
Hester Biosciences Limited
1,427.90
-343.61
-19.40%
IN:GUFICBIO
Gufic Biosciences Limited
289.75
-39.81
-12.08%
IN:INDOCO
Indoco Remedies Limited
187.60
-60.12
-24.27%
IN:MOREPENLAB
Morepen Laboratories Limited
37.98
-11.08
-22.58%
IN:UNICHEMLAB
Unichem Laboratories Limited
298.45
-361.95
-54.81%
Hester Biosciences Limited Corporate Events
Hester Biosciences to Shut Trading Window Ahead of FY26 Results
Mar 26, 2026
Hester Biosciences Limited has announced that its trading window for dealing in the company’s equity shares will be closed from 1 April 2026. The window will reopen 48 hours after the financial results for the quarter and year ended 31 March...
Hester Biosciences Publishes Extract of Q3 and Nine-Month FY2025 Results
Jan 31, 2026
Hester Biosciences Limited, listed on both BSE and NSE under the symbol HESTERBIO, has released an extract of its consolidated unaudited financial results for the quarter and nine-month period ended 31 December 2025, along with information on stan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.